NICE-CF: Colon Cancer Screening for adults with Cystic Fibrosis
Trial Objectives
.jpg?lang=en-US)
Adults with cystic fibrosis (CF) are at a higher risk of developing colon cancer due to a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.. Because of the increased risk, doctors recommend adults with CF begin receiving colon cancer screenings at age 40 or at age 30 if they are post-transplant. The purpose of the NICE-CF clinical trial is to compare the results of an at-home, stool-based test (e.g., a fecal immunochemical test AND Cologuard® test) to that of a colonoscopy, which is considered the best way to identify colon cancer. If the stool-based test is as reliable as a colonoscopy, researchers are hoping the convenience of an at-home test will encourage more adults with CF to get screened for colon cancer.
Participants will receive two at-home stool-based tests. Participants will be expected to complete a clinical colonoscopy as part of their routine standard of care.
Who Can Participate
Adults with CF ages 40-75 years old who have not had an organ transplant and are due for a colon cancer screening. Adults with CF ages 30-75 who have had an organ transplant and are due for a colon cancer screening.
Age: 30-75 Gender: Any
Estimated Time Commitment
Three to 12 months, depending on the completion of the at-home test and the colonoscopy
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
.jpg?lang=en-US)
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Saint Louis University
Principal Investigators
Jeffrey B. King, MD